Chumoukedima, Nagaland, April 30 (HBTV): British pharmaceutical giant AstraZeneca has admitted that its Covid-19 vaccine Covishield may lead to a rare side-affect known as Thrombosis with Thrombo Cytopenia Syndrome or TTS.      

This was admitted in a court document submitted to the UK High Court in February, following a lawsuit filed against the company, alleging serious harm and deaths linked to the vaccine.       

TTS is a condition in which blood clots form in unusual places in the body, and platelet count in the blood drops.             

TTS symptoms include severe headaches, stomach pain, swelling in the legs, breathing trouble, and problems with thinking or seizures.    

The World Health Organization reported in 2023 that TTS emerged as a new adverse event following immunization in individuals vaccinated with COVID-19 non-replicant adenovirus vector-based vaccines, including the AstraZeneca COVID-19 ChAdOx-1 vaccine and the Johnson & Johnson (J&J) Janssen COVID-19 Ad26.COV2-S vaccines.